LIFECORE BIOMEDICAL, INC. Increase (Decrease) in Notes Receivables
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase (Decrease) in Notes Receivables of $635.00 thousand for the 9-month period ending 2016-02-28, per its 10-Q filed 2016-03-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInNotesReceivables · last filed 2016-03-30
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for the quarter ending 2016-02-28 was $14.00K, a 99.39% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for the quarter ending 2015-11-29 was $799.00K.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for the quarter ending 2015-08-30 was -$178.00K, a 106.31% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for the quarter ending 2015-05-31 was $949.00K.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for fiscal 2015 was $5.69M, a 19.48% increase from fiscal 2014.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for fiscal 2014 was $4.76M, a 14.14% increase from fiscal 2013.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for fiscal 2013 was $4.17M, a 12.81% increase from fiscal 2012.
- LIFECORE BIOMEDICAL, INC. increase (decrease) in notes receivables for fiscal 2012 was $3.70M, a 20.37% increase from fiscal 2011.
| Period end | Increase (Decrease) in Notes Receivables 3 month | Increase (Decrease) in Notes Receivables 3 month as first filed | Increase (Decrease) in Notes Receivables 6 month | Increase (Decrease) in Notes Receivables 6 month as first filed | Increase (Decrease) in Notes Receivables 9 month | Increase (Decrease) in Notes Receivables 9 month as first filed | Increase (Decrease) in Notes Receivables 12 month |
|---|---|---|---|---|---|---|---|
| 2016-02-28 | $14.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $813.00K derived: sum of 2 quarters · filed 2016-03-30 | $635.00K 10-Q · filed 2016-03-30 | $1.58M derived: sum of 4 quarters · filed 2016-03-30 | |||
| 2015-11-29 | $799.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | $621.00K 10-Q · filed 2016-01-07 | $1.57M derived: sum of 3 quarters · filed 2016-01-07 | $3.85M derived: sum of 4 quarters · filed 2016-03-30 | |||
| 2015-08-30 | -$178.00K 10-Q · filed 2015-10-01 | $771.00K derived: sum of 2 quarters · filed 2015-10-01 | $3.05M derived: sum of 3 quarters · filed 2016-03-30 | $2.69M derived: sum of 4 quarters · filed 2016-03-30 | |||
| 2015-05-31 | $949.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-31 | $3.23M derived: sum of 2 quarters · filed 2016-03-30 | $2.87M derived: sum of 3 quarters · filed 2016-03-30 | $5.69M 10-K · filed 2015-07-31 | |||
| 2015-03-01 | $2.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-03-30 | $1.92M derived: sum of 2 quarters · filed 2016-03-30 | $4.74M 10-Q · filed 2016-03-30 | ||||
| 2014-11-30 | -$359.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-01-07 | $2.46M 10-Q · filed 2016-01-07 | |||||
| 2014-08-31 | $2.82M 10-Q · filed 2015-10-01 | ||||||
| 2014-05-25 | $4.76M 10-K · filed 2015-07-31 | ||||||
| 2013-05-26 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-31 | $4.17M 10-K · filed 2015-07-31 | |||||
| 2013-02-24 | $4.17M 10-Q · filed 2013-04-04 | ||||||
| 2012-05-27 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-08-01 | $2.11M derived: sum of 2 quarters · filed 2014-08-01 | $2.95M derived: sum of 3 quarters · filed 2014-08-01 | $3.70M 10-K · filed 2014-08-01 | |||
| 2012-02-26 | $2.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-04-04 | $2.95M derived: sum of 2 quarters · filed 2013-04-04 | $3.70M 10-Q · filed 2013-04-04 | -$3.70M 10-Q · filed 2012-03-28 | $9.84M derived: sum of 4 quarters · filed 2013-08-07 | ||
| 2011-11-27 | $834.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2013-01-04 | $1.59M 10-Q · filed 2013-01-04 | -$1.59M 10-Q · filed 2012-01-05 | $7.73M derived: sum of 3 quarters · filed 2013-08-07 | |||
| 2011-08-28 | $752.00K 10-Q/A · filed 2013-01-02 | -$752.00K 10-Q · filed 2011-10-05 | $6.89M derived: sum of 2 quarters · filed 2013-08-07 | ||||
| 2011-05-29 | $6.14M derived: 10-K 12 month − 10-Q 9 month · filed 2013-08-07 | $3.07M 10-K · filed 2013-08-07 | |||||
| 2011-02-27 | -$3.07M 10-Q · filed 2012-03-28 | ||||||
| 2010-11-28 | -$1.56M 10-Q · filed 2012-01-05 | ||||||
| 2010-08-29 | -$774.00K 10-Q · filed 2011-10-05 | ||||||
| 2010-05-30 | $3.03M 10-K · filed 2012-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |